Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia

He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.

Episode metadata supplied by the publisher feed · Published Nov 13, 2025

Embed this episode

Attribution link and audio player

Ready to play

Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia

0:00 4:12

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 4 minutes long.

This episode was published on November 13, 2025.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!